<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02061384</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000564</org_study_id>
    <nct_id>NCT02061384</nct_id>
  </id_info>
  <brief_title>RA-2 13-cis Retinoic Acid (Isotretinoin)</brief_title>
  <acronym>RA-2</acronym>
  <official_title>A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Oligoasthenoteratozoospermia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Men with infertility and normal hormone levels have few options for fertility treatment.
      Previous research work has suggested that men with infertility may have low levels of the
      active form of Vitamin A, called retinoic acid, in their testes. We think that giving men
      with low sperm counts retinoic acid may increase their sperm counts and improve their chances
      of fathering a pregnancy. We want to see if retinoic acid administration over twenty weeks
      can increase sperm production and help infertile men become fathers without the need for In
      vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI). We also want to see
      if adding calcitriol with retinoic acid will improve sperm motility in a sub-set of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 20 week, unblinded, two-arm pilot study to determine the impact of therapy with
      13-cis retinoic acid and calcitriol on sperm indices in infertile men. Twenty infertile men,
      ages 21-60 with abnormal sperm analyses will be enrolled for 20-week and given 20 mg 13-cis
      retinoic acid, twice daily. Subjects#11-#20 will also be administered calcitriol to see if
      adding calcitriol with Accutane will improve sperm motility. All subjects will be closely
      followed for side effects related to treatment. The impact of treatment on indices of
      spermatogenesis will be determined by monthly seminal fluid analyses.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total motile sperm</measure>
    <time_frame>Up to 20-weeks</time_frame>
    <description>Total motile sperm count in men treated with 13-cis retinoic acid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>13-cis retinoic acid serum level</measure>
    <time_frame>20-weeks</time_frame>
    <description>Concentration level of 13-cis retinoic acid in the serum of treated men</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse effects associated with treatment with 13-cis retinoic acid</measure>
    <time_frame>20-weeks</time_frame>
    <description>Number of adverse effects per subject associated with treatment with 13-cis retinoic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>13-cis retinoic acid Seminal Plasma Concentration</measure>
    <time_frame>Up to 20-weeks</time_frame>
    <description>13-cis retinoic acid concentration in semen of treated men</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if the additions of calcitriol with 13-cis retinoic acid can improve sperm motility</measure>
    <time_frame>20 weeks</time_frame>
    <description>improved sperm motility</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Male Infertility</condition>
  <condition>Klinefelter's Syndrome</condition>
  <condition>Y-chromosome Microdeletions</condition>
  <arm_group>
    <arm_group_label>13-cis retinoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcitriol 0.25 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13-cis retinoic acid</intervention_name>
    <description>Accutane is used for the treatment of severe acne</description>
    <arm_group_label>13-cis retinoic acid</arm_group_label>
    <other_name>Accutane</other_name>
    <other_name>Isotretinoin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>Calcitriol is a form of vitamin D given twice daily (BID)</description>
    <arm_group_label>Calcitriol 0.25 mcg</arm_group_label>
    <other_name>1,25-dihydroxyvitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be infertile men (no pregnancy with partner with normal cycles and
             normal hysterosalpingogram despite &gt;1 year of unprotected intercourse).

          -  Abnormal sperm analyses with a total, motile sperm count of less than 10 million sperm
             as assessed by semen analysis on two occasions separated by one week.

          -  In the opinion of the investigator, is able to comply with the protocol, understand
             and sign an informed consent and HIPAA (Health Insurance Portability and
             Accountability Act ) form.

        Exclusion Criteria:

          -  Men participating in another clinical trial

          -  Men not living in the catchment area of the clinic

          -  Clinically significant abnormal findings at screening

          -  Known genetic infertility (e.g. Klinefelter syndrome or Y-chromosome microdeletions),

          -  Hypogonadotropic hypogonadism (that might respond to gonadotropin injections),

          -  The use of anabolic steroids, illicit drugs, or the consumption of more than 4
             alcoholic beverages daily

          -  Severe mental health problems requiring medications

          -  Current therapy with retinoic acid (e.g. Accutane) or vitamin A.

          -  Score of greater than 15 on the Patient health questionnaire (PHQ9).

          -  Abnormal serum chemistry values according to local laboratory normal values which
             indicate liver or kidney dysfunction. Other abnormal lab values may also be
             exclusionary, at the discretion of the investigator

          -  Men with a personal history of serious psychiatric disorders

          -  Men currently receiving tetracycline containing medications

          -  Men currently receiving phenytoin

          -  Men with a history of inflammatory bowel disease

          -  Men with a history of bone disease

          -  Men who have used isotretinoin within eight weeks of the start of dosing

          -  Men with elevated serum triglycerides
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John K Amory, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jequier AM, Holmes SC. Primary testicular disease presenting as azoospermia or oligozoospermia in an infertility clinic. Br J Urol. 1993 Jun;71(6):731-5.</citation>
    <PMID>8102079</PMID>
  </reference>
  <reference>
    <citation>de Kretser DM. Male infertility. Lancet. 1997 Mar 15;349(9054):787-90. Review.</citation>
    <PMID>9074589</PMID>
  </reference>
  <reference>
    <citation>Schlegel PN. Nonobstructive azoospermia: a revolutionary surgical approach and results. Semin Reprod Med. 2009 Mar;27(2):165-70. doi: 10.1055/s-0029-1202305. Epub 2009 Feb 26. Review.</citation>
    <PMID>19247918</PMID>
  </reference>
  <reference>
    <citation>Napoli JL. Retinoic acid: its biosynthesis and metabolism. Prog Nucleic Acid Res Mol Biol. 1999;63:139-88. Review.</citation>
    <PMID>10506831</PMID>
  </reference>
  <reference>
    <citation>Center for Disease Control. Infertility Facts,m accessed at http://www.ede.gov/nchs/fastats/fertile.htm (June 3, 2013)</citation>
  </reference>
  <reference>
    <citation>Doyle TJ, Braun KW, McLean DJ, Wright RW, Griswold MD, Kim KH. Potential functions of retinoic acid receptor A in Sertoli cells and germ cells during spermatogenesis. Ann N Y Acad Sci. 2007 Dec;1120:114-30. Epub 2007 Sep 28.</citation>
    <PMID>17905941</PMID>
  </reference>
  <reference>
    <citation>Koubova J, Menke DB, Zhou Q, Capel B, Griswold MD, Page DC. Retinoic acid regulates sex-specific timing of meiotic initiation in mice. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2474-9. Epub 2006 Feb 6.</citation>
    <PMID>16461896</PMID>
  </reference>
  <reference>
    <citation>Anderson EL, Baltus AE, Roepers-Gajadien HL, Hassold TJ, de Rooij DG, van Pelt AM, Page DC. Stra8 and its inducer, retinoic acid, regulate meiotic initiation in both spermatogenesis and oogenesis in mice. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14976-80. doi: 10.1073/pnas.0807297105. Epub 2008 Sep 17.</citation>
    <PMID>18799751</PMID>
  </reference>
  <reference>
    <citation>Chung SS, Wang X, Wolgemuth DJ. Expression of retinoic acid receptor alpha in the germline is essential for proper cellular association and spermiogenesis during spermatogenesis. Development. 2009 Jun;136(12):2091-100. doi: 10.1242/dev.020040.</citation>
    <PMID>19465599</PMID>
  </reference>
  <reference>
    <citation>Dufour JM, Kim KH. Cellular and subcellular localization of six retinoid receptors in rat testis during postnatal development: identification of potential heterodimeric receptors. Biol Reprod. 1999 Nov;61(5):1300-8.</citation>
    <PMID>10529278</PMID>
  </reference>
  <reference>
    <citation>Lohnes D, Kastner P, Dierich A, Mark M, LeMeur M, Chambon P. Function of retinoic acid receptor gamma in the mouse. Cell. 1993 May 21;73(4):643-58.</citation>
    <PMID>8388780</PMID>
  </reference>
  <reference>
    <citation>Lufkin T, Lohnes D, Mark M, Dierich A, Gorry P, Gaub MP, LeMeur M, Chambon P. High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7225-9.</citation>
    <PMID>8394014</PMID>
  </reference>
  <reference>
    <citation>Kastner P, Mark M, Leid M, Gansmuller A, Chin W, Grondona JM, Décimo D, Krezel W, Dierich A, Chambon P. Abnormal spermatogenesis in RXR beta mutant mice. Genes Dev. 1996 Jan 1;10(1):80-92.</citation>
    <PMID>8557197</PMID>
  </reference>
  <reference>
    <citation>Ghyselinck NB, Vernet N, Dennefeld C, Giese N, Nau H, Chambon P, Viville S, Mark M. Retinoids and spermatogenesis: lessons from mutant mice lacking the plasma retinol binding protein. Dev Dyn. 2006 Jun;235(6):1608-22.</citation>
    <PMID>16586441</PMID>
  </reference>
  <reference>
    <citation>Hoting VE, Schütte B, Schirren C. [Isotretinoin treatment of acne conglobata. Andrologic follow-up]. Fortschr Med. 1992 Aug 20;110(23):427-30. German.</citation>
    <PMID>1398387</PMID>
  </reference>
  <reference>
    <citation>Vogt HJ, Ewers R. [13-cis-Retinoic acid and spermatogenesis. Spermatological and impulse cytophotometric studies]. Hautarzt. 1985 May;36(5):281-6. German.</citation>
    <PMID>3159708</PMID>
  </reference>
  <reference>
    <citation>Török L, Kádár L, Kása M. Spermatological investigations in patients treated with etretinate and isotretinoin. Andrologia. 1987 Nov-Dec;19(6):629-33.</citation>
    <PMID>3481225</PMID>
  </reference>
  <reference>
    <citation>Nya-Ngatchou JJ, Arnold SL, Walsh TJ, Muller CH, Page ST, Isoherranen N, Amory JK. Intratesticular 13-cis retinoic acid is lower in men with abnormal semen analyses: a pilot study. Andrology. 2013 Mar;1(2):325-31. doi: 10.1111/j.2047-2927.2012.00033.x. Epub 2012 Nov 29.</citation>
    <PMID>23413144</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. [Laboratory manual of the WHO for the examination of human semen and sperm-cervical mucus interaction]. Ann Ist Super Sanita. 2001;37(1):I-XII, 1-123. Italian.</citation>
    <PMID>11680039</PMID>
  </reference>
  <reference>
    <citation>Christiansen C, Christensen MS, Rødbro P, Hagen C, Transbøl I. Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest. 1981 Aug;11(4):305-9.</citation>
    <PMID>6795047</PMID>
  </reference>
  <reference>
    <citation>Riggs BL, Nelson KI. Effect of long term treatment with calcitriol on calcium absorption and mineral metabolism in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1985 Sep;61(3):457-61.</citation>
    <PMID>3926808</PMID>
  </reference>
  <reference>
    <citation>Falch JA, Odegaard OR, Finnanger AM, Matheson I. Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med Scand. 1987;221(2):199-204.</citation>
    <PMID>3035879</PMID>
  </reference>
  <reference>
    <citation>Caniggia A, Nuti R, Lore F, Martini G, Turchetti V, Righi G. Long-term treatment with calcitriol in postmenopausal osteoporosis. Metabolism. 1990 Apr;39(4 Suppl 1):43-9.</citation>
    <PMID>2325571</PMID>
  </reference>
  <reference>
    <citation>Ott SM, Chesnut CH 3rd. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989 Feb 15;110(4):267-74.</citation>
    <PMID>2913914</PMID>
  </reference>
  <reference>
    <citation>Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab. 2001 Aug;86(8):3618-28.</citation>
    <PMID>11502787</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>John Amory</investigator_full_name>
    <investigator_title>Professor, General Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
    <mesh_term>Klinefelter Syndrome</mesh_term>
    <mesh_term>Chromosome Deletion</mesh_term>
    <mesh_term>Sex Chromosome Aberrations</mesh_term>
    <mesh_term>Sex Chromosome Disorders of Sex Development</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

